AADI Profile
Aadi Bioscience, Inc., headquartered in Pacific Palisades, California, is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of precision therapies tailored for cancers characterized by genetic mutations affecting mTOR pathway genes. Established in 2007, Aadi has positioned itself at the forefront of oncological innovation, focusing on therapies that target specific molecular profiles associated with mTOR pathway activation.
Central to Aadi's portfolio is FYARRO, its lead drug candidate. FYARRO represents a unique formulation of sirolimus conjugated with albumin, engineered to optimize drug delivery and efficacy in targeted cancer treatments. Currently undergoing rigorous clinical evaluation, FYARRO is being assessed across a spectrum of cancers where mTOR pathway activation has been implicated, including indications that transcend specific tumor types and instead prioritize genomic alterations linked to mTOR pathway activation.
Beyond its flagship candidate, Aadi Bioscience maintains a robust pipeline aimed at expanding treatment options in oncology. The company leverages advanced genomic insights and bioinformatics to identify and validate potential therapeutic targets within the mTOR signaling pathway, continually exploring novel avenues to address unmet medical needs in cancer care. Aadi's commitment to scientific rigor and patient-centric innovation drives its efforts to translate cutting-edge research into tangible clinical advancements.
Collaborating closely with leading academic institutions and clinical partners, Aadi Bioscience is dedicated to accelerating the development of transformative therapies from preclinical stages through to regulatory approval and commercialization. By harnessing the power of precision medicine and leveraging strategic alliances across the healthcare ecosystem, Aadi remains steadfast in its mission to redefine standards of care and improve outcomes for patients grappling with genetically defined cancers.
|
